[{"address1": "333 Las Olas Way", "address2": "CU4 Suite 433", "city": "Fort Lauderdale", "state": "FL", "zip": "33301", "country": "United States", "phone": "954-515-0810", "website": "https://sunshinebiopharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Steve N. Slilaty Ph.D.", "age": 71, "title": "Chairman, President & CEO", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 640000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Camille  Sebaaly", "age": 64, "title": "CFO & Secretary", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 695000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Abderrazzak  Merzouki", "age": 59, "title": "Chief Science Officer & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 340000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marc  Beaudoin", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Malek  Chamoun", "age": 38, "title": "Chief Development Officer", "yearBorn": 1985, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert G. Ferreira", "age": 61, "title": "President of Sunshine Bio Investments Inc", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.02, "open": 3.02, "dayLow": 2.98, "dayHigh": 3.09, "regularMarketPreviousClose": 3.02, "regularMarketOpen": 3.02, "regularMarketDayLow": 2.98, "regularMarketDayHigh": 3.09, "beta": -1.102, "forwardPE": 0.015115115, "volume": 103105, "regularMarketVolume": 103105, "averageVolume": 172282, "averageVolume10days": 84510, "averageDailyVolume10Day": 84510, "marketCap": 6078958, "fiftyTwoWeekLow": 2.42, "fiftyTwoWeekHigh": 640.0, "priceToSalesTrailing12Months": 0.19942792, "fiftyDayAverage": 2.9815, "twoHundredDayAverage": 87.96608, "currency": "USD", "enterpriseValue": -7521877, "profitMargins": -0.12071, "floatShares": 1122306, "sharesOutstanding": 1999660, "sharesShort": 321526, "sharesShortPriorMonth": 222316, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.2626, "heldPercentInsiders": 0.00234, "heldPercentInstitutions": 0.00635, "shortRatio": 1.12, "shortPercentOfFloat": 0.26299998, "impliedSharesOutstanding": 2012900, "bookValue": 20.057, "priceToBook": 0.15057088, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -3679607, "trailingEps": -378.25, "forwardEps": 199.8, "lastSplitFactor": "1:20", "lastSplitDate": 1723075200, "enterpriseToRevenue": -0.247, "enterpriseToEbitda": 1.709, "52WeekChange": -0.99511325, "SandP52WeekChange": 0.39389753, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SBFM", "underlyingSymbol": "SBFM", "shortName": "Sunshine Biopharma Inc.", "longName": "Sunshine Biopharma, Inc.", "firstTradeDateEpochUtc": 1644935400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7909c686-ce8d-3dd2-8c10-62221258e4a3", "messageBoardId": "finmb_78729055", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.02, "targetHighPrice": 300.0, "targetLowPrice": 300.0, "targetMeanPrice": 300.0, "targetMedianPrice": 300.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 11507745, "totalCashPerShare": 10.235, "ebitda": -4400769, "totalDebt": 577358, "quickRatio": 2.921, "currentRatio": 4.859, "totalRevenue": 30481982, "debtToEquity": 2.458, "revenuePerShare": 1143.489, "returnOnAssets": -0.09907, "returnOnEquity": -0.15792, "freeCashflow": -11566942, "operatingCashflow": -10909907, "revenueGrowth": 0.673, "grossMargins": 0.30408, "ebitdaMargins": -0.14437, "operatingMargins": -0.13633001, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]